<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423059</url>
  </required_header>
  <id_info>
    <org_study_id>koh01</org_study_id>
    <nct_id>NCT00423059</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy</brief_title>
  <official_title>Histologic Changes of Fibrovascular Membrane Associated With Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab (AvastinÂ®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <brief_summary>
    <textblock>
      Recently, intravitreal bevacizumab (Avastin) injection has gained popularity as a potential
      treatment of intraocular neovascularization (CNV) associated with age related macular
      degeneration and diabetic retinopathy. The efficacy of the drug is thought to be related with
      its pharmacologic blockade of VEGF.

      The purpose of this study is to determine the effect of the intravitreal bevacizumab on the
      fibrovascular membrane associated with proliferative diabetic retinopathy by objective
      histologic evaluation.

      The patients scheduled for vitrectomy for tractional fibrovascular membrane due to
      proliferative diabetic retinopathy will be randomized into two treatment groups. The one will
      receive conventional vitrectomy and the other group will receive intravitreal bevacizumab
      injection one week before the scheduled vitrectomy. The fibrovascular membrane will be
      excised during surgery and fixated for histologic examinations. The expression of VEGF and
      PEDF, a potent inhibitor of angiogenesis, will be evaluated in the fibrovascular membrane by
      immunohistochemistry. The results will be compared between two treatment groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date>March 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>expression level of VEFG</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>PEDG</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>complication rate</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tractional retinal detachment recently involving the macula with fibrovascular
             membrane due to proliferative diabetic retinopathy

          -  Severe fibrovascular proliferation progressing after appropriate panretinal
             photocoagulation

        Exclusion Criteria:

          -  Uncontrolled systemic hypertension

          -  Recent history of myocardiac infarction within 6 months

          -  Recent history of cerebrovascular accident within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jun Koh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Yonsei University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006 Jul-Aug;26(6):699-700.</citation>
    <PMID>16829817</PMID>
  </reference>
  <reference>
    <citation>Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006 Oct;142(4):685-8.</citation>
    <PMID>17011869</PMID>
  </reference>
  <reference>
    <citation>Matsuoka M, Ogata N, Minamino K, Matsumura M. Expression of pigment epithelium-derived factor and vascular endothelial growth factor in fibrovascular membranes from patients with proliferative diabetic retinopathy. Jpn J Ophthalmol. 2006 Mar-Apr;50(2):116-20.</citation>
    <PMID>16604386</PMID>
  </reference>
  <reference>
    <citation>Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006 Oct;113(10):1695.e1-15.</citation>
    <PMID>17011951</PMID>
  </reference>
  <reference>
    <citation>Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006 Jul;142(1):155-8.</citation>
    <PMID>16815267</PMID>
  </reference>
  <reference>
    <citation>Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye (Lond). 2006 Dec;20(12):1474-5. Epub 2006 May 5.</citation>
    <PMID>16680105</PMID>
  </reference>
  <reference>
    <citation>Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006 Mar;26(3):275-8.</citation>
    <PMID>16508426</PMID>
  </reference>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <last_update_submitted>March 12, 2007</last_update_submitted>
  <last_update_submitted_qc>March 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2007</last_update_posted>
  <keyword>intravitreal bevacizumab</keyword>
  <keyword>proliferative diabetic retinopathy</keyword>
  <keyword>VEGF</keyword>
  <keyword>PEDF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

